IL251595B - Ataxia telangiectasia and rad3-related protein kinase inhibitors - Google Patents
Ataxia telangiectasia and rad3-related protein kinase inhibitorsInfo
- Publication number
- IL251595B IL251595B IL251595A IL25159517A IL251595B IL 251595 B IL251595 B IL 251595B IL 251595 A IL251595 A IL 251595A IL 25159517 A IL25159517 A IL 25159517A IL 251595 B IL251595 B IL 251595B
- Authority
- IL
- Israel
- Prior art keywords
- rad3
- atr
- protein kinase
- kinase inhibitors
- ataxia telengiectasia
- Prior art date
Links
- 206010003591 Ataxia Diseases 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063176P | 2014-10-13 | 2014-10-13 | |
| US201562104274P | 2015-01-16 | 2015-01-16 | |
| PCT/US2015/055317 WO2016061097A1 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251595A0 IL251595A0 (en) | 2017-06-29 |
| IL251595B true IL251595B (en) | 2022-04-01 |
Family
ID=55654998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251595A IL251595B (en) | 2014-10-13 | 2017-04-05 | Ataxia telangiectasia and rad3-related protein kinase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9663535B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3207031B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6678679B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102569226B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107108527B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015333738B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017007708B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2963973C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2879441T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL251595B (cg-RX-API-DMAC7.html) |
| MX (1) | MX389198B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016061097A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389198B (es) | 2014-10-13 | 2025-03-20 | Atrin Pharmaceuticals LLC | Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr). |
| WO2017180723A1 (en) * | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
| EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| SI3651768T1 (sl) | 2017-07-13 | 2024-05-31 | Chempartner Corporation | Heterociklični inhibitorji atr kinaze |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| WO2019055657A1 (en) * | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | BAF COMPLEX MODULATION COMPOUNDS AND METHODS OF USE |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CN110357905B (zh) * | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
| US11980613B2 (en) | 2018-07-12 | 2024-05-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for reversing HIV latency using BAF complex modulating compounds |
| CN110950890B (zh) * | 2018-09-27 | 2022-07-01 | 北京赛林泰医药技术有限公司 | 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂 |
| CN113454080B (zh) | 2018-10-30 | 2025-10-28 | 修复治疗公司 | 化合物、药物组合物和制备化合物的方法以及其使用方法 |
| JP7774621B2 (ja) | 2020-10-16 | 2025-11-21 | シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド | 三複素環誘導体、その医薬組成物及び使用 |
| WO2023201320A1 (en) | 2022-04-14 | 2023-10-19 | Atrin Pharmaceuticals LLC | Atr inhibitors |
| KR20250023494A (ko) | 2022-06-15 | 2025-02-18 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103265477B (zh) * | 2003-02-26 | 2017-01-11 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| SI3354650T1 (sl) * | 2008-12-19 | 2022-06-30 | Vertex Pharmaceuticals Incorporated | Spojine, uporabne kot zaviralci ATR kinaze |
| EP2569287B1 (en) * | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| EP2686323A1 (en) | 2011-03-16 | 2014-01-22 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
| AP2014007881A0 (en) * | 2012-03-06 | 2014-08-31 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| JP6111276B2 (ja) * | 2012-03-17 | 2017-04-05 | ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ | コンホメーション制約された全合成されたマクロ環化合物 |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| MX389198B (es) | 2014-10-13 | 2025-03-20 | Atrin Pharmaceuticals LLC | Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr). |
-
2015
- 2015-10-13 MX MX2017004515A patent/MX389198B/es unknown
- 2015-10-13 EP EP15850553.7A patent/EP3207031B1/en active Active
- 2015-10-13 WO PCT/US2015/055317 patent/WO2016061097A1/en not_active Ceased
- 2015-10-13 CA CA2963973A patent/CA2963973C/en active Active
- 2015-10-13 ES ES15850553T patent/ES2879441T3/es active Active
- 2015-10-13 KR KR1020177012838A patent/KR102569226B1/ko active Active
- 2015-10-13 US US14/881,680 patent/US9663535B2/en active Active
- 2015-10-13 AU AU2015333738A patent/AU2015333738B2/en active Active
- 2015-10-13 BR BR112017007708A patent/BR112017007708B8/pt active Search and Examination
- 2015-10-13 CN CN201580067182.7A patent/CN107108527B/zh active Active
- 2015-10-13 JP JP2017538930A patent/JP6678679B2/ja active Active
-
2017
- 2017-04-05 IL IL251595A patent/IL251595B/en unknown
- 2017-04-27 US US15/498,631 patent/US9981989B2/en active Active
-
2018
- 2018-04-12 US US15/951,302 patent/US10196405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10196405B2 (en) | 2019-02-05 |
| JP6678679B2 (ja) | 2020-04-08 |
| IL251595A0 (en) | 2017-06-29 |
| AU2015333738B2 (en) | 2020-03-26 |
| BR112017007708B8 (pt) | 2023-10-24 |
| US20180230168A1 (en) | 2018-08-16 |
| KR20170082532A (ko) | 2017-07-14 |
| KR102569226B1 (ko) | 2023-08-22 |
| US20160102104A1 (en) | 2016-04-14 |
| CN107108527A (zh) | 2017-08-29 |
| CA2963973A1 (en) | 2016-04-21 |
| BR112017007708A2 (pt) | 2017-12-19 |
| EP3207031B1 (en) | 2021-04-14 |
| MX2017004515A (es) | 2017-10-31 |
| WO2016061097A1 (en) | 2016-04-21 |
| BR112017007708A8 (cg-RX-API-DMAC7.html) | 2017-12-19 |
| US9981989B2 (en) | 2018-05-29 |
| MX389198B (es) | 2025-03-20 |
| JP2017531041A (ja) | 2017-10-19 |
| CA2963973C (en) | 2023-01-10 |
| EP3207031A4 (en) | 2018-02-14 |
| BR112017007708B1 (pt) | 2023-07-25 |
| AU2015333738A1 (en) | 2017-05-04 |
| US20170226130A1 (en) | 2017-08-10 |
| EP3207031A1 (en) | 2017-08-23 |
| ES2879441T3 (es) | 2021-11-22 |
| US9663535B2 (en) | 2017-05-30 |
| CN107108527B (zh) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| IL251595B (en) | Ataxia telangiectasia and rad3-related protein kinase inhibitors | |
| IL262867B (en) | kras g12c inhibitors | |
| IL289766A (en) | tfpi inhibitory antibodies and their uses | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| EP3149008B8 (en) | Certain protein kinase inhibitors | |
| SI3277681T1 (sl) | Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinaze | |
| ZA201700786B (en) | Protein kinase c inhibitors and methods of their use | |
| SI3936153T1 (sl) | Zaviranje ataksije telangiektazije in z RAD3 povezane beljakovine (ATR) | |
| IL254916A0 (en) | Inhibitors and their uses | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| EP3186247A4 (en) | Protein kinase inhibitors | |
| EP3224248A4 (en) | Certain protein kinase inhibitors | |
| TH1501006103A (th) | สารยับยั้งโปรตีนไคเนส | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses |